This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Amedisys Inc
2/24/2022
Greetings. Welcome to the Emeticis Q4 2021 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Nick Moscato, SVP of Finance. Thank you. You may begin.
Thank you, Operator, and welcome to the Emeticis Investor Conference Call to discuss the results of the fourth quarter and year-ended December 31st, 2021. A copy of our press release, supplemental slides, and related form 8K filing with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Emeticis will be Paul Cucero, Chairman and Chief Executive Officer, Chris Girard, President and Chief Operating Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer. Also joining us is Dave Kimmerly, Chief Legal and Government Affairs Officer. Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the safe harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Emeticis today. The company assumes no obligations to update information provided on this call to reflect subsequent events other than is required under applicable securities laws. These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our forms 10-K, 10-Q, and 8-K. In addition, as required by SEC Regulation G, A reconciliation of any non-GAAP measure mentioned during our call today to the most comparable GAAP measure will also be available in our forms 10-K, 10-Q, and 8-K. Thank you. And now I'll turn the call over to Amedisys Chairman and CEO, Paul Cucero.
Thanks, Nick, and welcome to the Amedisys fourth quarter and year-end 2021 earnings call. We have a lot to discuss on today's call. But as this will be my last earnings call, before we dive in, I first want to thank and acknowledge Nick Moscato for all of his fine work on these calls over the years. He has taken us to a new level, and I'm very appreciative of what he has done for me and Amedisys. I would also like to express my sincere appreciation for all of the 21,000 Amedisys employees whether you are at a patient's bedside or support those providing the industry's best-in-class care. At Amedisys, we put quality before everything, and the unwavering dedication of all of our employees has been delivering great patient care. And this dedication to quality continues to be my greatest point of pride and largest source of inspiration. I humbly thank you for all that you do. 2021 was a topsy-turvy year, unlike any other. And before I turn it over to Chris and Scott, I'd like to highlight a few of the many successes we've had during the year. Though CMS has frozen the publicly reported home health stars metrics, we never let our foot off the gas on quality. We never will. It's simply in our DNA. In 2021, we continued to make strides. Using industry data and internal benchmarks, we proved that once again, a medicis is second to none in home health quality. You can't deliver great care without great caregivers. And we have made human capital a passion, recruitment and turnover a science, and focused hard and creatively on building and retaining our incredibly important clinical staff. I want to thank and acknowledge Sharon Bernes and her team for putting us at the vanguard by constantly reminding us it's all about our people. As healthcare labor markets become more challenged nationwide, Amedisys was able to drive our clinical turnover down an additional 9% from 2020 to 2021. Additionally, To fuel our present and future growth, we increased our recruitment numbers by driving a 27% increase in recruited headcount. Recruitment, retention, and turnover are continuously our biggest initiatives, as having enough clinical capacity to serve our patients in our fast-growing industries has never been more paramount. Demand is not going to be the issue. Supply is. and we are improving our capabilities here every day. While still facing many challenges brought upon by COVID in both home health and hospice, in 2021, we still grew our EBITDA 10%, and we grew our EBITDA margin 40 basis points while delivering $189 million in cash flow from operations, and we beat Q4 during the peak of Omicron. We took our cash flow and we invested in the inorganic growth of our business, resulting in the acquisition of four CONs, VNA, Evolution, and changed the game with our acquisition of Contessa. By acquiring Contessa, we took a meaningful step in differentiating ourselves as more than just a home health and hospice company. The leader in its space, Contessa builds risk-bearing, tech-enabled, hospital at home, SNP at home, and capitated palliative platforms. It has become our platform for future innovation and new models for care delivered in the home. We further continued to think outside the box and challenge our thinking by investing in ConnectRN, an innovative solution for recruiting nurses and for engaging with our current clinical workforce differently. In the coming weeks, you'll hear of other investments that continue to push us to innovate and differentiate in this constantly evolving market. Finally, and yet most importantly, we delivered the highest quality care, performing more than 11.5 million visits for more than 445,000 patients in 2021. Amongst the backdrop of COVID-19 disruption and its impact on all of healthcare, 2021 is a year I'm exceptionally proud of. The lead-in quote to our 2022 strategic plan was a quote from the ancient Greek philosopher Heraclitus. You can't step into the same river twice. Amedisys enters 2022 as a new, expanded, and complete organization well poised for continued growth and even further differentiation in our expanding solutions for the home. With that, I'll turn it over to President and COO and incoming CEO, Chris Gerard, to run us through the operational updates. Chris?
You're reading a preview of the AMED Q4 2021 earnings call.
Free account.